# An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients

> **NCT06923891** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Vanguard Research Group** · enrollment: 172 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Xanomeline/Trospium

## Key facts

- **NCT ID:** NCT06923891
- **Lead sponsor:** Vanguard Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-16
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2025-04-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06923891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06923891, "An Open-Label Study to Evaluate the Efficacy and Tolerability of Xanomeline/Trospium In First Episode/Early Phase Schizophrenia Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06923891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*